Clinical Trials

MainTitle

Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

This study is not yet open for participant recruitment. (see Contacts and Locations)

Verified December 2019 by National Institute of Allergy and Infectious Diseases (NIAID)

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator
The University of Texas Health Science Center, Houston

Information provided by (Responsible Party)
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier
NCT04216589

First received: December 30, 2019
Last updated: December 30, 2019
Last Verified: December 2019
History of Changes
Purpose

Purpose

The purpose of this study is to evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in adults living with HIV, central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.

Condition Intervention Phase
HIV Infections
Non-Alcoholic Fatty Liver Disease

Drug : Semaglutide
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-Arm, Open-Label, Pilot Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study)

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures

  • Change (absolute) in IHTG (%) [ Time Frame: Measured from pre-entry to Week 24 ]
Secondary Outcome Measures:
  • Change (percent) in IHTG (%) [ Time Frame: Measured from pre-entry to Week 24 ]
  • Change (absolute) in body mass index (BMI) [ Time Frame: Measured from Week 0 to Weeks 12 and 24 ]
  • Change (absolute) in body weight [ Time Frame: Measured from Week 0 to Weeks 12 and 24 ]
  • Change (absolute) in minimum waist circumference (WC) [ Time Frame: Measured from Week 0 to Weeks 12 and 24 ]
  • Level of IHTG (%) [ Time Frame: Measured at pre-entry and Week 24 ]
  • Occurrence of premature discontinuation of study treatment [ Time Frame: Measured through Week 24 ]
  • Occurrence of Grade ≥3 adverse event (or, for aspartate aminotransferase (AST)/alanine aminotransferase (ALT), elevation ≥3x entry values or ≥500 U/L, whichever is lower) that are related to study treatment [ Time Frame: Measured through Week 24 ]
    Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017
  • Change (absolute) in insulin resistance (HOMA-IR) [ Time Frame: Measured from Week 0 to Weeks 12 and 24 ]
  • Change (absolute) in glucose [ Time Frame: Measured from Week 0 to Weeks 12 and 24 ]
  • Change (absolute) in lipid profiles (triglycerides, HDL cholesterol, LDL cholesterol, and total cholesterol) [ Time Frame: Measured from Week 0 to Weeks 12 and 24 ]
  • Presence of metabolic syndrome [ Time Frame: Measured at Weeks 0, 12, and 24 ]
    Metabolic syndrome is defined as having ≥3 of the following: increased minimum WC, high triglyceride level, reduced HDL cholesterol, increased blood pressure, and elevated fasting blood glucose, based on current guidelines.

Estimated Enrollment: 50
Anticipated Study Start Date: June 29, 2020
Estimated Study Completion Date: February 28, 2022
Estimated Primary Completion Date: August 29, 2021 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: Semaglutide
All participants will receive a dose of 0.25 mg of semaglutide weekly starting at study entry, followed by 0.5 mg weekly starting at Week 2, and then 1.0 mg weekly from Weeks 4 through 24.
Drug: Semaglutide

Administered subcutaneously

Detailed Description:

This study will evaluate the effects of semaglutide on intra-hepatic triglyceride (IHTG) content in adults living with HIV, central adiposity, insulin resistance or pre-diabetes, and hepatic steatosis.
All participants will receive semaglutide subcutaneously once weekly for 24 weeks, followed by 24 weeks of observation off of the study drug. IHTG will be quantified by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) evaluations at two time points during the study.
Participants will attend several study visits through Week 48. Participants will complete food diaries, adherence and strength assessments, and report on hypoglycemia, vision changes, physical activity, diet, quality of life, and acceptability of study drug. Blood will be collected at all visits and stool samples at two visits.
Participants must remain on their non-study-provided antiretroviral therapy (ART) throughout the study.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria:

  • HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load.
    • NOTE: The term "licensed" refers to a US Food and Drug Administration (FDA)-approved kit, which is required for all investigational new drug (IND) studies, or for sites located in countries other than the United States, a kit that has been certified or licensed by an oversight body within that country and validated internally. Non-US sites are encouraged to use US FDA-approved methods for IND studies.
    • WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load.
  • Two separate reports of HIV-1 RNA measurements <50 copies/mL, and no HIV-1 RNA measurement >500 copies/mL, during the 48 weeks prior to entry. One of the HIV-1 RNA values must be the screening visit value, and the other value obtained between 24 and 48 weeks prior to entry.
    • NOTE: All values must have been reported from a US laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent, or at any network-approved non-US laboratory that is Virology Quality Assurance (VQA) certified.
  • No change in antiretroviral therapy (ART) in the 24 weeks prior to entry.
    • NOTE A: Modifications of ART formulation (e.g., from standard formulation to fixed dose combination or single tablet regimen) will be permitted.
    • NOTE B: Within-class substitutions are not permitted.
  • No plan to change ART for the study duration.
  • A minimum WC measurement of ≥95cm for individuals assigned male sex at birth or ≥94cm for individuals assigned female sex at birth within 30 days prior to pre-entry.
    • NOTE: For transgender study participants, sites should use the parameter that matches sex assigned at birth.
  • At least one of the following drawn within 30 days prior to pre-entry by any US laboratory that has a CLIA certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs:
    • Fasting plasma glucose 100-125 mg/dL (refer to the study protocol for a definition of fasting).
    • HbA1c between 5.7 and <6.5%
    • Homeostatic model assessment of insulin resistance (HOMA-IR) >3.0 (Refer to calculator: https://www.mdcalc.com/homa-ir-homeostatic-model-assessment-insulin-resistance)
  • Hepatic fat content (i.e., IHTG) ≥5%, as determined by liver magnetic resonance imaging-proton density fat fraction (MRI-PDFF) within 14 days prior to entry (and within 30 days after screening).
    • NOTE: Refer to the study protocol for more details.
  • CD4+ T-cell count ≥200 cells/mm^3 within 30 days prior to pre-entry (may be from standard of care) at any US laboratory that has a CLIA certification or its equivalent, or at any network-approved non-US laboratory that is Immunology Quality Assurance (IQA) certified.
  • The following laboratory values obtained within 30 days prior to pre-entry by any US laboratory that has a CLIA certification or its equivalent, or at any network-approved non-US laboratory that operates in accordance with GCLP and participates in appropriate external quality assurance programs:
    • Absolute neutrophil count (ANC) >750 cells/mm^3
    • Hemoglobin >10 g/dL for individuals assigned male at birth and >9 g/dL for individuals assigned female at birth
    • Creatinine clearance (CrCl) ≥50 mL/min, as calculated by the CKD-Epi equation. Please refer to A5371 protocol-specific web page (PSWP) for the website link to calculate CrCl using the CKD-Epi calculator.
    • NOTE: Calculations will be done without using cystatin C. Please refer to the A5371 Manual of Operating Procedures (MOPS) for further details.
    • Aspartate aminotransferase (AST) (SGOT) <3 x ULN.
    • Alanine aminotransferase (ALT) (SGPT) <3 x ULN.
    • Fasting triglyceride level ≤500 mg/dL.
    • NOTE A: See the study protocol for a definition of fasting.
    • NOTE B: If level is >500 mg/dL, level may be rechecked within the screening window.
  • For individuals prescribed daily medications with anti-inflammatory properties, including but not limited to, statins and chronic corticosteroids (inhaled corticosteroids exempt), the doses must be stable as determined by the site investigator for ≥3 months prior to study entry, and the individual should have no active plans to change dosing during the study period.
  • For individuals taking daily lipid-lowering medications (such as statins, fibrates, niacin, fish oil), the doses must be stable as determined by the site investigator for ≥3 months prior to study entry, and the individual should have no active plans to change dosing during the study period.
    • NOTE: Lipid-lowering equivalents for niacin and fish oil are ≥1 g and ≥3 g daily, respectively.
  • Ability and willingness of participant to provide informed consent
  • Willingness and ability to use auto-inject pen weekly for approximately 24 weeks.
  • Willingness and ability to undergo MRI scans.
    • NOTE: Anxiolytics will not be provided through the study but may be provided at site expense.
  • For persons capable of pregnancy, a negative serum or urine pregnancy test (urine test must have a sensitivity of <25 mIU/mL) both 1) at screening (within 30 days prior to pre-entry MRI) and 2) within 3 days before or at entry (prior to registration into study) by any US clinic or laboratory that has a CLIA certification or its equivalent, or is using a point of care (POC)/ CLIA-waived test, or at any network-approved non-US laboratory or clinic that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs.
    • NOTE: Individuals capable of pregnancy are defined as individuals who have reached menarche and who have not been post-menopausal for at least 24 consecutive months (i.e., have had menses within the preceding 24 months), and have not undergone surgical sterilization such as hysterectomy, bilateral oophorectomy, tubal ligation, or salpingectomy.
  • If participating in sexual activity that could lead to the participant becoming pregnant, the participant must agree to use contraception while on study drug (approximately 24 weeks) and for 2 months following the last dose of study drug. At least one of the following must be used:
    • Intrauterine device (IUD)
    • Hormone-based contraceptive
    • Partner sterilization (i.e., vasectomy) and is the sole partner for the participant.
    • NOTE: Self-report of partner sterilization is acceptable.
  • For individuals taking Vitamin E (any dose), the dose must be stable as determined by the site investigator for more than 1 year prior to entry.
  • Adults age ≥18 years.
  • Willingness to be contacted by telephone or e-mail by study staff throughout the study.


Exclusion Criteria:
  • Known active hepatitis C virus (HCV) infection, defined as a detectable HCV RNA within 24 weeks prior to study entry.
    • NOTE A: Individuals with HCV RNA below the limit of quantitation for >24 weeks prior to study entry are eligible, i.e., individuals who have been treated for hepatitis C are eligible if they have completed therapy >24 weeks prior to study entry, and/or individuals who spontaneously cleared hepatitis C virus are eligible as long as they have had undetectable HCV RNA for >24 weeks. HCV RNA testing is not provided by the study.
    • NOTE B: If HCV antibody testing has not been performed in the 5 years prior to screening and the participant does not have history of cured HCV infection, HCV antibody testing should be repeated at screening.
    • NOTE C: If screening HCV antibody is performed, and is reactive or positive, please refer individual for HCV RNA testing through routine clinical care.
  • Active/chronic hepatitis B (HBV), defined as a positive hepatitis B surface antigen (HBsAg) at screening.
    • NOTE A: HBsAg testing is only required at screening if HBV laboratory results are not available within the last 5 years prior to screening and individual does not have documented immunity.
    • NOTE B: if HBsAg positive, individual is not eligible and should be referred for clinical evaluation through routine care.
  • Acute Hepatitis A virus.
  • Known active severe delayed gastric emptying, as determined by the site investigator.
  • Gain or loss of >5% body weight within 12 weeks prior to study entry.
    • NOTE: Self-report recall is acceptable.
  • Any plans to change diet or exercise regimen significantly, except for the adoption of study provided suggestions for diet and exercise, within the study period.
    • NOTE: Significantly refers to intent to join a weight-loss program such as Weight Watchers, or start a specific diet (such as ketogenic or very low carbohydrate).
  • Known acute or chronic liver disease with cirrhosis or portal hypertension.
  • History of liver transplant.
  • Breastfeeding or plans to become pregnant.
  • Current diagnosis of diabetes mellitus or current use of diabetes medications, or a laboratory measurement of hemoglobin A1c ≥6.5% at screening.
    • NOTE: Stable use of metformin (i.e., for ≥12 weeks) for indication other than diabetes (e.g., polycystic ovarian syndrome or pre-diabetes/impaired fasting glucose) may be permitted with approval of the Clinical Management Committee (CMC).
  • Known retinopathy (excluding remote history of cotton wool spots)
  • Personal or family (first-degree relative) history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).
  • History of unexplained hypercalcemia corrected for albumin that is >10.5 mg/dL.
  • Use of any immunomodulatory (including prednisone equivalent of ≥10 mg), HIV vaccine, investigational therapy, or TNF-α therapy within 3 months prior to study entry.
  • Use of human growth hormone, tesamorelin, supraphysiologic testosterone to achieve therapeutic blood levels, or any use of other anabolic steroids within 3 months prior to study entry or plans to start these while on study.
    • NOTE: Chronic, stable hormone replacement therapy ≥3 months prior to entry in men with diagnosed hypogonadism or transgender person on masculinizing hormonal therapy is permitted.
  • Use of estrogens or progesterones at supraphysiologic doses within 3 months prior to study entry.
    • NOTE: Stable doses used for contraception, post-menopausal hormone replacement or feminizing hormone therapy for transgender persons ≥3 months prior to entry is permitted.
  • Known allergy/sensitivity or any hypersensitivity to components of study drug or its formulation.
  • Current serious illness requiring systemic treatment and/or hospitalization.
    • NOTE: The individual can be rescreened when they complete therapy or are clinically stable as determined by the site investigator.
  • Use of GLP-1 agonists within 24 weeks prior to study entry.
  • Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Excessive consumption of alcohol of ≥3 months within 90 days prior to screening, defined as:
    • Consuming ≥5 alcoholic drinks for men or consuming ≥4 alcoholic drinks for women during a single occasion (i.e., at the same time or within a couple of hours of each other), or
    • ≥3 drinks on 4 or more days of the week on average for men or ≥2 drinks on 4 or more days of the week on average for women.
    • NOTE: For transgender study participants, sites should use the parameter that matches sex assigned at birth.
  • Known chronic pancreatitis or more than one episode of pancreatitis ever in the past.
  • Inability to keep study product at 36°F to 46°F (2°C to 8°C) prior to first use, or to maintain the study product at a controlled room temperature between 59°F and 86°F (15°C to 30°C) following first use.
  • Intent to use any medication likely to cause significant changes in weight during the study period.
    • NOTE: A list of medications in this category is in the study protocol.
  • Use of stavudine within 12 months prior to study entry.
  • Prior bariatric surgery (e.g., lap band, gastric sleeve, or Roux-en-Y bypass surgery) or major gastric surgery or plans to undergo weight reduction surgery while on study.
  • Individuals with any metal, implantable devices (e.g., pacemakers, prosthetics), or shrapnel, per standard MRI exclusion criteria.
  • Any condition that the site investigator believes would make the individual unsuitable
for participation.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT04216589

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)
The University of Texas Health Science Center, Houston

Investigators

Study Chair: Kristine Erlandson, MD, MS University of Colorado Hospital CRS
Study Chair: Jordan E. Lake, MD, MSc Houston AIDS Research Team CRS
More Information

More Information


Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)  
ClinicalTrials.gov Identifier: NCT04216589   History of Changes  
Other Study ID Numbers: ACTG A5371  
  38453  
Study First Received: December 30, 2019  
Last Updated: December 30, 2019  
Individual Participant Data    
Plan to Share IPD: Yes  

Studies a U.S. FDA-regulated Drug Product: Yes  
Studies a U.S. FDA-regulated Device Product: No  

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

NAFLD
HIV
semaglutide

Additional relevant MeSH terms:
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Metabolic Syndrome
Insulin Resistance
Cardiovascular Diseases
Insulin

ClinicalTrials.gov processed this data on March 27, 2020
This information is provided by ClinicalTrials.gov.